Biotechnology Application Case Analysis
8 weeks · 0 milestones
Conduct a real case analysis of a specific named biotechnology application: a named CRISPR therapy in clinical trials (using a named IND in the ClinicalTrials.gov registry), a specific named synthetic biology product with regulatory status, or a named agricultural biotech product with a published safety assessment. The analysis must address three dimensions: (1) scientific validity — what does the evidence actually show about efficacy and mechanism? (2) regulatory status — what approvals exist, what is still pending, and what evidence gaps remain? (3) ethical implications — what are the genuine contested trade-offs, using a named ethical framework applied explicitly? Public clinical trial registries, regulatory agency filings (FDA, EMA), and peer-reviewed literature provide the evidence base, all publicly accessible. Reviewed by a biotechnology researcher, bioethicist, or industry practitioner who challenges whether the evidence you cited is sufficient to support your conclusions about efficacy — requiring you to evaluate evidence quality, not just summarise published claims.
Milestone map
Milestone map
3 milestones
Select a specifically scoped biotechnology application — not 'CRISPR' broadly, but a concrete application such as 'base editing for sickle cell disease' or 'CAR-T cell therapy for B-cell lymphoma' — and gather primary sources covering the technical mechanism, current development status, and known challenges. Analysis of publicly available literature, patent databases, and regulatory filings requires no physical lab access.
Proof required
Submit your precisely stated research question and an annotated bibliography of 12–15 sources (peer-reviewed papers, patent filings, regulatory documents, or clinical trial registrations) with each annotation stating the source's contribution to understanding the mechanism, status, or challenge being analysed.
What gets checked
- Question is specific enough to make a 'this application has solved X but not Y' analysis possible — not broad enough to require a textbook-length treatment
- Source list covers at minimum three source types: peer-reviewed research, regulatory or clinical trial registration, and one independent secondary analysis
- Each annotation states the source's specific relevance to the analysis question — not just a content summary